SAB BIOTHERAPEUTICS, INC. (SABS)

(10% Negative) SAB BIOTHERAPEUTICS, INC. (SABS) Announces Delay in Congress Trials for Brisbane Due to Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment